ArticleCancers2023
Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- CRAFITY and PALBI Define a Machine Learning-Supported Prognostic Framework in Hepatocellular Carcinoma-Data from an Eastern European Cohort with Low Macrotrabecular-Massive Prevalence.Diseases (Basel, Switzerland) · 2026Article
- Evaluating liver reserve in direct-acting antiviral-treated hepatitis C patients: do we have better surrogate markers?Journal of gastroenterology · 2026Article
- NLR-PALBI Score and Its Grading: Predicting Overall Survival of Patients with Primary Liver Cancer Undergoing Transcatheter Arterial Chemoembolisation.Journal of hepatocellular carcinoma · 2026Article
- Article
- Liver Functions in Patients with Chronic Liver Disease and Liver Cirrhosis: Correlation of FLIS and LKER with PALBI Grade and APRI.Current medical imaging · 2025Article
- Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.The oncologist · 2025Article
- Decoding prognosis in dengue-induced hepatitis: Model for end-stage liver diseaseWorld journal of gastroenterology · 2025Article
- Bilirubin metabolism in relation to cancer.Frontiers in oncology · 2025Review
- Comparison of Albumin-Bilirubin, Platelet-Albumin-Bilirubin, and Child-Pugh scores to predict overall survival in patients with stage C hepatocellular carcinoma with liver cirrhosis treated with c-TACE.Frontiers in oncology · 2025Article
- Validation of prognostic scores for predicting acute liver failure and in-hospital death in patients with dengue-induced severe hepatitis.World journal of gastroenterology · 2024Article
- Clinical Results of Holmium-166 Radioembolization with Personalized Dosimetry for the Treatment of Hepatocellular Carcinoma.Journal of personalized medicine · 2024Article
- A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.JHEP reports : innovation in hepatology · 2024Article
- Liver Function-Related Indicators and Risk of Gallstone Diseases-A Multicenter Study and a Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2024Article
- A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements.Journal of hepatocellular carcinoma · 2024Article
- Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency.International journal of molecular sciences · 2023Article
- Article
- Review
- Added Value of Cone-Beam Computed Tomography for Detecting Hepatocellular Carcinomas and Feeding Arteries during Transcatheter Arterial Chemoembolization Focusing on Radiation Exposure.Medicina (Kaunas, Lithuania) · 2023Article
- Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
(1) Background: The severity of liver functional reserve plays an important role in the management of hepatocellular carcinoma (HCC). Noninvasive models such as the model for end-stage liver disease (MELD), albumin-bilirubin (ALBI) grade and easy (EZ)-ALBI grade, platelet-albumin-bilirubin (PALBI) and platelet-albumin (PAL) are used to evaluate liver dysfunction. We aimed to compare the prognostic performance of these four albumin-based models against MELD in HCC patients undergoing transarterial chemoembolization (TACE). (2) Methods: A total of 1038 treatment naïve HCC patients who received TACE as the primary treatment were enrolled. A multivariate Cox model was used to determine independent survival predictors. (3) Results: Multivariate analysis revealed that higher serum creatinine and α-fetoprotein level, vascular invasion, large tumor size, ALBI grades 2-3, EZ-ALBI grades 2-3, PALBI grades 2-3, PAL grades 2-3, but not the MELD score, were independent predictors associated with decreased survival in different Cox models. Among these models, the PALBI grade had the highest homogeneity and lowest corrected Akaike information criteria value, followed by EZ-ALBI, PAL, ALBI and, lastly, MELD. (4) Conclusions: All four albumin-based liver reserve models are better prognostic tools than MELD score in HCC patients undergoing TACE. Of these, the PALBI score is the best model to evaluate the liver reserve and should be considered a surrogate marker in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.